Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;36(3):897-900.
doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21.

Second versus first wave of COVID-19 in patients with MPN

Affiliations

Second versus first wave of COVID-19 in patients with MPN

Tiziano Barbui et al. Leukemia. 2022 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Overall survival by waves of coronavirus pandemic.
Kaplan-Meier curves of overall survival by the two waves of Covid-19 (A) and multivariate Cox proportional hazard model for mortality during the acute phase (B).

References

    1. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–45. doi: 10.1016/S2352-3026(20)30251-9. - DOI - PMC - PubMed
    1. Jiménez M, Roldan E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Adv. 2021. Online ahead of print as 10.1182/bloodadvances.2021006101. - PMC - PubMed
    1. Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020;4:5966–75. doi: 10.1182/bloodadvances.2020003170. - DOI - PMC - PubMed
    1. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35:485–93. doi: 10.1038/s41375-020-01107-y. - DOI - PMC - PubMed
    1. Sheather SJ. Density estimation. Stat Sci. 2004;19:588–97. doi: 10.1214/088342304000000297. - DOI

Publication types

LinkOut - more resources